Eiger BioPharmaceuticals Inc EIGRQ
$8.50 $0.50 (6.25%) 1D
Last Updated: Sep 27, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
Eiger BioPharmaceuticals Inc. Stock Analysis EIGRQ
United States Health Care Nano Cap Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. The company is headquartered in Palo Alto, California and currently employs 25 full-time employees. The firm is focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, and Peginterferon Lambda (lambda) for COVID-19. LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection. LNF has demonstrated dose-dependent activity in reducing HDV viral load both as a monotherapy and in combination with ritonavir (RTV) and/or PEG IFN-alfa-2a. Lambda is a type III, well-tolerated interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections.
Eiger BioPharmaceuticals Inc (EIGRQ) Chart
Financial Metrics & Statements of Eiger BioPharmaceuticals Inc (EIGRQ)
FAQ's for Eiger BioPharmaceuticals Inc (EIGRQ)
- As of August 2026, Eiger BioPharmaceuticals Inc EIGRQ is classified as not covered according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Eiger BioPharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Eiger BioPharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Eiger BioPharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Eiger BioPharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Eiger BioPharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Eiger BioPharmaceuticals Inc (EIGRQ)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
